- Abridge and Kaiser Permanente debut Care Signals
- Built to Serve: The Day That Reminds Us Why We Chose Dentistry
- Journalists Catch You Up on Fauci Hearing, Peptides, and Kids’ Caffeine Consumption
- CMS finalizes 2.3% hospital pay bump, mandatory joint replacement model: 9 things to know
- How ambulatory shifts are reshaping perioperative strategy
- Cyclosporiasis cases top 18,000: 3 updates
- How Allegheny Health Network Strengthened its Foundation for IV Compounding Safety with Automation and Standardization¹
- Health plan customer service reps have AI in their ear
- Centene’s buyouts could have a $315M+ price tag for the rest of the year
- Medicare pay cut sparks specialty battle over skin cancer care
- Cardiovascular Institute of New England provides notice of data incident
- CMS locks in 2.3% inpatient hospital base pay increase, nudges back CJR-X Model start date
- Why autonomy — not just capital — is winning over cardiologists
- The $36 vs. $95 problem: How RVU negotiations are skewing physician pay
- Mississippi hospital board member, former CEO remembered as advocate for rural communities
- Pennsylvania SUD treatment locator reaches 146K users
- Top 10 dental, DSO stories in July
- Ohio youth treatment facility faces scrutiny over reported abuse: 8 notes
- What dental leaders told us in July
- Urban hospital closures and net change, by state
- ADSO sues Colorado Dental Board over practice ownership rule
- New patient acquisition is the top growth driver for dental practices: Report
- 20 new behavioral health projects to know
- Nurses, patients protest North Star Health Alliance ASC closure
- No Surprises Act under attack by payers: 8 things to know
- Dental staffing wages up 23% since 2021: ADA
- AtlantiCare appoints anesthesiology, gastroenterology physician leaders
- Consumer dental spending up 24% over 10 years: 5 stats to know
- Baylor Scott & White joint venture expands outpatient behavioral health services
- 5 DSOs making headlines
- VA to explore GLP-1 treatment for alcohol use disorder: 4 notes
- A $5B wave of M&A hits the ASC industry
- FTC Sues Hims & Hers Over Health Privacy And Billing Practices
- 145 physician medical groups led all healthcare M&A sectors in Q1
- 10 new ASCs in July
- Healthcare exec, telemedicine company owner sentenced for $35M DME fraud scheme
- Amylyx demystifies post-bariatric hypoglycemia with patient education website
- What Dad Eats Before Conception May Influence Baby's Health
- Family History Plays Role In Genetic Risk For Breast Cancer, Researchers Find
- A look at employers' attitudes toward ICHRAs
- Revised 340B Rebate Model Pilot Program moves forward, despite provider pushback
- Function Health lands $450M in growth financing to scale tech-enabled preventive health
- Daiichi Sankyo flags accounting error, as shares tank despite revenue beat
- AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market
- Op-ed: Hospitals on the edge, a time for CMS to do no harm
- Daily Routine Key To Good Health, Study Says
- Alignment Healthcare boasts 32% revenue jump in Q2, lifts 2026 outlook
- Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
- Psilocybin Therapy Helps Ease Veterans' Severe PTSD, Pilot Study Finds
- Newsom Reverses On Long-Sought Paid Leave Benefit For California Teachers
- Nicotine Levels Are Rising Among Teens Who Vape, New Study Warns
- The Newest Federally Recognized Tribe Wants Better Healthcare. It May Be On Its Own.
- They Worked To Protect Public Health. Now They Want the Public’s Votes.
- 27 new behavioral health study findings to know
- 21 state behavioral health policy updates
- What will fuel the next wave of DSO growth
- Dentists’ biggest staffing headaches
- Shionogi makes the call on COVID pill Xocova TV spot
- Psilocybin-assisted therapy reduced PTSD symptoms: 3 notes
- Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod
- Psychedelics, peptides and GLP-1s
- How 'physician-led' care team models tackle primary care's workforce problem
- How 7 systems divert behavioral health patients from the ED
- WellSpan Health, Hippocratic AI ink ‘multi-year’ partnership with plans to co-develop clinical AI agents
- Kaiser faces complaint over automated behavioral health triage system
- Free research hub Nila aims to demystify menopause, other hormone conditions
- Scientists Defend Fauci's Pandemic Work As Senate Hearing Turns Bitter
- Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie
- Study Questions Effectiveness of Antihistamines in Easing Eczema
- Vaping Is Likely Reshaping The Future Of Cancer In The US, Study Argues
- Weekly Rundown: Counsel Health rolls out white label AI care platform; Community Health Network launches MyChart AI assistant
- New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat
- Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026
- Waystar boosts 2026 outlook as AI-powered RCM solutions gain traction with providers
- YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort
- Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic
- Sugar Consumption Early In Life Linked To Increased Dementia Risk, World War II-Era Data Show
- Work Stress Harming Middle-Age Sleep, Study Says
- RFK Jr.'s Gardasil litigation ties subject to fresh lawmaker scrutiny after Merck settlement
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
- Hospice's Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
- Cell Phone Ownership Linked To Lower Reading Skills In Elementary Students
- Listen to the Latest ‘KFF Health News Minute’
- Abortion Drug Law in Louisiana Heightens Hemorrhage Risk for Pregnant Patients
- Medicaid Insurers’ Contracts on the Line in Tight Governor’s Race
- Teladoc Health trims 2026 revenue forecast amid challenges with BetterHelp insurance shift
- Cigna CEO: Express Scripts seeing 'significant early interest' from clients for new rebate-free PBM model
- Viatris runs into FDA roadblock after advertising on-the-go use of cystic fibrosis inhaler
- Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
- FTC sues Hims & Hers over data privacy, billing practices
- CMS' proposed 340B reimbursement cut—who wins, and who loses?
- Virtual care helps patients improve their gambling disorder symptoms, Birches Health finds
- Case Western Reserve University launches next-generation healthcare leadership program
- Lilly, Resilience commit $750M to boost US diabetes, obesity med production
- CMS ending Medicare Part D subsidy program
- Red Cross Declares Rare National Blood Supply Crisis Amid Summer Shortfall
- Not Just Pregnancy Fatigue: Could It Be Sleep Apnea?
- More Women Drinking During Pregnancy
- Wellstar Health System lays off 761 corporate, administrative staff
- Biogen flips '26 guidance from expected decline to sales increase
- Teva’s innovation engine offsets generics slump, leaving one analyst ‘shocked’ by Ajovy’s surge
- Talking To Your Baby? Eye Contact Is Key To Language Development, Experiment Shows
- Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026
- Leapfrog launches expanded ASC public reporting program
- Cyclospora Boosts Fears That Deadlier Foodborne Outbreaks Are Ahead
- DoorDash, GrubHub Delivering Junk Food To 1 In 4 Teens During School Hours
- Uninsured but Undaunted, a Surgical Patient Searched the Globe for a Deal
- Trump Has Quietly Throttled an Agency Devoted to the Safety of American Healthcare
- Hospice’s Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn
- Humana plans more market exits for 2027, CFO says
- PMCPA sanctions melatonin drugmaker over misleading information
- CG Life embraces next-gen era in merger with AI-native agency The Considered+AI
- How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval
- Fifth Death Reported In NYC Legionnaires' Disease Outbreak
- Many Young Adults Aren't Ready To Manage Their Own Healthcare, Poll Finds
- Can A Daily Multivitamin Help You Stay Active As You Age?
- Stellarus launches AI-powered health plan customer service representative copilot
- Prebiotic Soda Health Claims Questioned In New Nutrition Study
- Family-Based Childhood Obesity Program Helps Kids Cut Weight, Become Healthier
- To Afford Aging In Place, Older Adults Turn To 'Golden Girls' Housing
- Breakfast Can Help Teens Make Better Food Choices Throughout Their Day, Study Says
- Newsom Reverses on Long-Sought Paid Leave Benefit for Teachers in California
- FDA Panel Backs Two Peptides For Compounding, Rejects One
- How Accurate Are Photo-Based Calorie Apps? 4 Are Put To The Test
- Popular School Cafeteria Meals Need An Update To Meet Healthy Food Standards, Researchers Say
- Ovarian Syndrome Quadruples Heart Disease Risk In Women, Major Study Concludes
- Weed-Killing Chemical, Glyphosate, Linked To Premature Births In Humans, Study Says
- 'The Child Is Terrified': Doctors On Front Lines Of Measles Comeback Speak Out
- 'Yo-yo' Weight Loss Linked To Decline In Muscle Mass
- FDA Advisers Dismiss Safety Warnings, Back Four Peptide Treatments
- Frequent Marijuana Use Linked To Higher Stress Hormone Levels
- Back Pain? Try Swimming, Study Says
- Ozempic Cuts Down Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
- Money Problems Might Make Your Brain Old Before Its Time, Study Suggests
- Black MS Patients Dying Younger Than White Ones, Study Finds
- Headstands and Summervaults: A Statement on Crypto Vaults and Lending Strategies
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Seeking Public Comment on Seeking Public Capital: Remarks Before the Small Business Capital Formation Advisory Committee
- Remarks to the Small Business Capital Formation Advisory Committee
- Statement on Regulation E-Delivery
- Paper Taper: Statement on Proposed Regulation E-Delivery
- Statement on Proposed Regulation E-Delivery
- Senate HELP committee advances nominees for CDC director, HHS preparedness head
- Remarks before the American-Hellenic Chamber of Commerce
- Remarks at the Society for Corporate Governance Conference
- Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
- AdaptHealth Investigates Data Breach After Social Engineering Attack, Possible Link to ShinyHunters Emerges
- Statement on the 2026 Regulatory Agenda
- Applying Agentic AI to Healthcare Delivery: The Key to True Transformation
- From Compliance to Clinical Action: Fixing the Broken Loop in Post-Market Surveillance
Michigan healthcare freedom community forum
The breath-taking extent to which health insurance interferes between patient and clinician comes to life in this Associated Press documentary.
Photo library clipped due to length, but remains available at the link.
Limits to anti-nausea pill coverage wear on cancer patients and doctors
Cancer patients can ward off waves of vomiting after treatment with a relatively cheap anti-nausea pill, but some are running into coverage limits.
Doctors say restrictions on the number of tablets patients receive can hurt care. Pharmacy benefit managers say their limits guard against overuse, and they offer workarounds to get more tablets.
In between sit patients, who might ration pills or opt for less effective help for a dreaded side effect of radiation or chemotherapy.
The conflict shows how an array of coverages and poor communication can complicate even simple acts of care in the fragmented U.S. health care system.“This is sort of the dirty underbelly of the current health care environment,” said oncologist Dr. Fumiko Chino. “Insurance companies and pharmacy benefit managers are somehow weirdly ending up in my exam room, standing between me and my patients.”
Steven Manetta takes at least a half dozen pills daily to help keep a form of leukemia in remission. For more than a year, he rationed his go-to anti-nausea pill, ondansetron, known by the brand-name Zofran.
Manetta’s coverage through CVS Caremark paid for 18 ondansetron pills every 21 days. That forced him to sometimes use alternatives that make him extremely drowsy in order to stretch his supply. He only recently got approval for a 90-day supply.
“It’s just like an extra thing to think about all the time,” the 33-year-old Lemont, Illinois, resident said. “When you’re on so many medications, the ones with the least side effects are the ones you always want to reach for.”
Ondansetron hit the U.S. market more than 30 years ago. It was the first in a series of drugs that gave doctors a better way to control nausea and vomiting, said Dr. Alexi Wright, a Dana-Farber Cancer Institute oncologist who teaches at Harvard.
Wright and other cancer specialists call ondansetron a cornerstone treatment because of its relative safety, effectiveness and limited side effects.
The price doesn’t hurt either: Thirty tablets of ondansetron can cost under $12 through prescription discount websites.
Pharmacists and doctors say they’ve dealt with restrictions on anti-nausea drugs like ondansetron for years. Wright says she finds the limits “infuriating” in part because the drug is affordable.
More than half the plans sold on the U.S. individual insurance marketplace limit the number of ondansetron tablets that patients can get, according to preliminary results from a study by Chino and Michael Anne Kyle, a University of Pennsylvania researcher.
Pharmacist Yen Nguyen frequently sees these restrictions, including the limits from CVS Caremark that Manetta encountered.
“Over four or five months of chemotherapy, you’re fighting for dimes and nickels here,” said Nguyen, executive director of pharmacy for the Houston-area practice Oncology Consultants.
Jennette Murphy paid cash for ondansetron when her cancer treatment started earlier this year because she couldn’t get coverage for the amount her doctor requested. Then she got a letter telling her the drug wouldn’t be covered.
“It freaked me out,” the Tehachapi, California, resident said. “I’m like, ‘Really? Have you ever been through chemo?’”
Pharmacy benefit managers say they set limits based partly on the treatment and offer several ways for doctors to request more.
Prime Therapeutics limits 4- and 8-milligram prescriptions of ondansetron to 21 tablets over 30 days. That helps provide “maximum dosing” for seven days of treatment a month, chief clinical officer David Lassen said in an email.
He said quantity limits are approved by independent doctors and pharmacists. They help prevent waste and excessive use that may not be safe.
CVS Caremark spokesman Mike DeAngelis said his company bases limits on Food and Drug Administration guidelines. He added that the company can make a decision on requests for more tablets in less than 24 hours.
Doctors say they don’t always know when patients will need more.
Coverage limits vary, and some patients may not tell their doctor that they got a smaller-than-desired amount. Also, nausea intensity can be hard to gauge with newer treatments.
Chino says she wants patients to start with 90 tablets of ondansetron, enough to take the drug three times a day for a month if needed. But she often sees limits of 21 or 30 tablets.
“The fact that there’s still restrictive patterns on this very useful medication is insane,” said Chino, who recently moved from Memorial Sloan Kettering in New York to MD Anderson in Houston.
Limits can hurt patients who have big copayments for each refill or trouble getting to the drugstore, noted Dr. Ramy Sedhom, an oncologist and palliative care specialist with Penn Medicine Princeton Health.
“I have a lot of patients who only go to the pharmacy once a month when their niece or nephew is in town to pick up the (prescriptions),” he said.
If patients run out of ondansetron, even for a few days, uncontrolled vomiting can send them to emergency rooms or force a treatment pause, doctors say.
Murphy, the cancer patient, has avoided all of that. She said coverage started for ondansetron after her City of Hope cancer center doctor requested it.
She faces a stretch of chemotherapy cycles that will extend well into the fall. The treatments leave her bedridden for days with nausea even while taking ondansetron.
“I would hate to not have it,” she said.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.























